Appointments at Clearstone Central Laboratories, NexMed and RRD – People on the move
Clearstone Central Laboratories has named Rose Buot as vice president (VP) of global quality assurance. Buot has more than 13 years of quality assurance experience in the preclinical, clinical and pharma manufacturing sectors.
In addition, Bernie Clark has joined Clearstone as marketing director. Clark previously worked at MDS Inc’s corporate marketing group and was involved during the sale of the central labs business to Clearstone.
Scott Tarrant has been appointed as chief business officer at RRD International. Tarrant has previously worked at Gene Logic, TherImmune Research, Nalco Chemical and Xceleron.
NexMed has expanded its senior management team within its operating subsidiaries, naming Terry Ladd as VP of business development at Bio-Quant and Richard Martin as VP of chemistry at NexMed (USA), Inc.
Ladd has more than 20 years experience in preclinical sales at companies including Calvert Laboratories, MDS Pharma Services and Chrysalis International. Martin has held positions at RetroVirox, Exelixis and Tanabe Research Laboratories.
John Pietruski has retired from the board of directors at PDI. Pietruski has worked on the board for 12 years, during which time PDI went through its initial public offering (IPO).
Collaborative Drug Discovery (CDD) has appointed Andrea Barry to lead its efforts to expand into the pharma market. Barry has previously worked at MDL, SciTegic and Accelrys.
Matt Gorman has joined Compliance Implementation Services (CIS) as director of government pricing programs. Gorman has worked as a contract consultant for CIS, as well as Kromite, and also held positions at KPMG.
QPS has named Eric Solon as fellow, autoradiography DMPK. Solon has worked as director of autoradiography at QPS since 2002 and also held positions at DuPont Pharmaceuticals, Novartis and Schering-Plough.